The effect of metabolic syndrome on head and neck cancer incidence risk: a population-based prospective cohort study

Table 5 Risk of head and neck cancer according to CRP and the joint effect of MS and CRP

	No. of cases/person-years	Model 1		Model 2		Model 3
	No. of cases/person-years	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
CRP
< 1.00 mg/dL	223/1155432	Reference		Reference		Reference
≥ 1.00 mg/dL	531/1750092	1.39[1.18, 1.62]	<0.001	1.44[1.23, 1.68]	<0.001	1.21[1.03, 1.42]	0.021
Joint effect of MS and CRP	p-interaction=0.501
No MS/CRP < 1.00 mg/dL	181/1027524	Reference		Reference		Reference
No MS/CRP ≥ 1.00 mg/dL	327/1153876	1.42[1.19, 1.72]	<0.001	1.45[1.21, 1.73]	<0.001	1.22[1.02, 1.47]	0.033
MS/CRP < 1.00 mg/dL	42/127908	1.50[1.07, 2.10]	0.018	1.30[0.93, 1.82]	0.126	1.20[0.85, 1.68]	0.298
MS/CRP ≥ 1.00 mg/dL	204/596216	1.58[1.29, 1.93]	<0.001	1.61[1.31, 1.96]	<0.001	1.29[1.05, 1.58]	0.017

Model 1: unadjusted
Model 2: age and gender-stratified model
Model 3: additionally adjusted for education, ethnic, index of multiple deprivation, alcohol consumption, smoking status, physical activity, fruit and vegetable intake, and NASIDS use

ISSN: 2049-3002